Based on this YouTube video's total view count of 317 views and industry-standard rates, the estimated total earning is $0 - $1 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Life Sciences Virtual Investor Forum - MetaVia Inc. (Nasdaq: MTVA) with 317 views, 0 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

This video is part of the @OTCMarketsGroup Life Sciences Virtual Investor Forum by Virtual Investor Conferences, a @b2idigital Featured Conference, held on March 11th & 12th, 2026. MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects. Watch the full MetaVia Inc. (Nasdaq: MTVA) presentation and request meetings with management at: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5259493/metavia-inc-nasdaq-mtva?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC Any questions or need assistance setting up meetings, contact Joseph Azizo, Capital Markets Associate at B2i Digital: [email protected]

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.